References
1. Peter JG, Lehloenya R, Dlamini S, et al. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. J Allergy Clin Immunol Pract. 2017;5(3):547-563.
2. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy.2014;69(4):420-437.
3. Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy. 2004;34(10):1597-1601.
4. Wong SX, Tham MY, Goh CL, Cheong HH, Chan SY. Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore. Pharmacol Res Perspect. 2019;7(2):e00469.
5. Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? Am J Clin Dermatol. 2019;20(2):217-236.
6. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
7. Rossi CM, Beretta FN, Traverso G, Mancarella S, Zenoni D. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Clin Mol Allergy. 2020;18:19.
8. Schmid-Grendelmeier P, Steiger P, Naegeli MC, et al. Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract. 2021;9(1):481-483.e482.
9. Balconi SN, Lopes NT, Luzzatto L, Bonamigo RR. Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance?Int J Dermatol. 2021;60(1):125-126.
10. Manjaly Thomas ZR, Leuppi-Taegtmeyer A, Jamiolkowski D, et al. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.J Allergy Clin Immunol. 2020;146(4):786-789.
11. Novak N, Peng W, Naegeli MC, et al. SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?Allergy. 2020;Online ahead of print.
12. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on ’Cutaneous manifestations in COVID-19: a first perspective’ by Recalcati S. J Eur Acad Dermatol Venereol. 2020;34(7):e299-e300.
13. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.
14. Riggioni C, Comberiati P, Giovannini M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020;75(10):2503-2541.
15. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83(1):280-285.
16. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564-1581.
17. Xue X, Mi Z, Wang Z, Pang Z, Liu H, Zhang F. High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2. J Invest Dermatol.2020;S0022-202X(20):31602-X.
18. Jamiolkowski D, Mühleisen B, Müller S, Navarini AA, Tzankov A, Roider E. SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet.2020;396(10251):598-599.
19. Brüggen MC, Strobl J, Koszik F, et al. Subcutaneous White Adipose Tissue of Healthy Young Individuals Harbors a Leukocyte Compartment Distinct from Skin and Blood. J Invest Dermatol. 2019;139(9):2052-2055.e2057.
20. Eling N, Damond N, Hoch T, Bodenmiller B. <em>cytomapper</em>: an R/Bioconductor package for visualisation of highly multiplexed imaging data. bioRxiv. 2020:2020.2009.2008.287516.
21. M. K. Building Predictive Models in R Using the caret Package. Journal of Statistical Software.2008;28(5).
22. Schapiro D, Jackson HW, Raghuraman S, et al. histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. Nat Methods.2017;14(9):873-876.
23. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One.2014;9(4):e95192.
24. Lind L, Ärnlöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis.Atherosclerosis. 2015;242(1):205-210.
25. Söderlund S, Christiansson L, Persson I, et al. Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leuk Res.2016;50:95-103.
26. Lang C, Masenga J, Semango G, et al. Evidence for different immune signatures and sensitization patterns in sub-Saharan versus central European Atopic Dermatitis patients.J Eur Acad Dermatol Venereol. 2020.
27. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med.2020;26(5):681-687.
28. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy.2020;75(11):2829-2845.
29. Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy.2020;75(10):2445-2476.
30. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;S2213-2600(20):30404-30405.
31. Sinha P, Matthay MA, Calfee CS. Is a “Cytokine Storm” Relevant to COVID-19? JAMA Internal Medicine. 2020;180(9):1152-1154.
32. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.2020;395(10229):1054-1062.
33. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.Lancet. 2020;395(10239):1763-1770.
34. de la Rica R, Borges M, Gonzalez-Freire M. COVID-19: In the Eye of the Cytokine Storm.Frontiers in Immunology. 2020;11(2313).
35. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.
36. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.
37. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741.
38. Luo M, Liu J, Jiang W, Yue S, Liu H, Wei S. IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19. JCI Insight.2020;5(13).
39. Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107-1118.
40. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell. 2020;182(6):1419-1440.e1423.
41. Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med.2010;2(46):46ra62.
42. Yang F, Chen SA, Wu X, Zhu Q, Luo X. Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol. 2018;28(1):13-25.
43. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-611.
44. Ushigome Y, Mizukawa Y, Kimishima M, et al. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Clin Exp Allergy.2018;48(11):1453-1463.